Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1

Victor DeGruttola, Laurel A Beckett, Robert W. Coombs, Jean Marie Arduino, Henry H. Balfour, Suraiya Rasheed, F. Blaine Hollinger, Margaret A. Fischl, Paul Volberding

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Serum p24 antigen levels were examined in subjects from three clinical trials of zidovudine to determine whether the pattern of change in serum p24 antigen during the first 8-16 weeks of therapy was associated with human immunodeficiency virus type 1 (HIV-1) disease progression or death. Among 406 patients with AIDS and a first episode of Pneumocystis carinii pneumonia, 65% had measurable pretreatment concentrations of serum p24 antigen (≥10 ng/mL). Changes during treatment were not associated with reduced mortality. In 637 mildly symptomatic patients, 24% had measurable concentrations, and changes were marginally associated with increased time until more advanced disease. Among 683 asymptomatic patients, 18% had measurable concentrations, and changes were not associated with increased time until progression. Despite the small number of clinical events and the low rate of serum p24 antigen positivity in the latter two studies, pretreatment serum p24 antigen levels were predictive of clinical outcome; subsequent measurements appear to be of limited use in evaluating zidovudine therapy.

Original languageEnglish (US)
Pages (from-to)713-721
Number of pages9
JournalJournal of Infectious Diseases
Volume169
Issue number4
StatePublished - Apr 1994
Externally publishedYes

Fingerprint

Zidovudine
HIV-1
Clinical Trials
Antigens
Serum
Pneumocystis Pneumonia
Virus Diseases
Disease Progression
Acquired Immunodeficiency Syndrome
Therapeutics
Mortality

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. / DeGruttola, Victor; Beckett, Laurel A; Coombs, Robert W.; Arduino, Jean Marie; Balfour, Henry H.; Rasheed, Suraiya; Hollinger, F. Blaine; Fischl, Margaret A.; Volberding, Paul.

In: Journal of Infectious Diseases, Vol. 169, No. 4, 04.1994, p. 713-721.

Research output: Contribution to journalArticle

DeGruttola, V, Beckett, LA, Coombs, RW, Arduino, JM, Balfour, HH, Rasheed, S, Hollinger, FB, Fischl, MA & Volberding, P 1994, 'Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1', Journal of Infectious Diseases, vol. 169, no. 4, pp. 713-721.
DeGruttola, Victor ; Beckett, Laurel A ; Coombs, Robert W. ; Arduino, Jean Marie ; Balfour, Henry H. ; Rasheed, Suraiya ; Hollinger, F. Blaine ; Fischl, Margaret A. ; Volberding, Paul. / Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. In: Journal of Infectious Diseases. 1994 ; Vol. 169, No. 4. pp. 713-721.
@article{6b342f918c864556bc83f70e67e67036,
title = "Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1",
abstract = "Serum p24 antigen levels were examined in subjects from three clinical trials of zidovudine to determine whether the pattern of change in serum p24 antigen during the first 8-16 weeks of therapy was associated with human immunodeficiency virus type 1 (HIV-1) disease progression or death. Among 406 patients with AIDS and a first episode of Pneumocystis carinii pneumonia, 65{\%} had measurable pretreatment concentrations of serum p24 antigen (≥10 ng/mL). Changes during treatment were not associated with reduced mortality. In 637 mildly symptomatic patients, 24{\%} had measurable concentrations, and changes were marginally associated with increased time until more advanced disease. Among 683 asymptomatic patients, 18{\%} had measurable concentrations, and changes were not associated with increased time until progression. Despite the small number of clinical events and the low rate of serum p24 antigen positivity in the latter two studies, pretreatment serum p24 antigen levels were predictive of clinical outcome; subsequent measurements appear to be of limited use in evaluating zidovudine therapy.",
author = "Victor DeGruttola and Beckett, {Laurel A} and Coombs, {Robert W.} and Arduino, {Jean Marie} and Balfour, {Henry H.} and Suraiya Rasheed and Hollinger, {F. Blaine} and Fischl, {Margaret A.} and Paul Volberding",
year = "1994",
month = "4",
language = "English (US)",
volume = "169",
pages = "713--721",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1

AU - DeGruttola, Victor

AU - Beckett, Laurel A

AU - Coombs, Robert W.

AU - Arduino, Jean Marie

AU - Balfour, Henry H.

AU - Rasheed, Suraiya

AU - Hollinger, F. Blaine

AU - Fischl, Margaret A.

AU - Volberding, Paul

PY - 1994/4

Y1 - 1994/4

N2 - Serum p24 antigen levels were examined in subjects from three clinical trials of zidovudine to determine whether the pattern of change in serum p24 antigen during the first 8-16 weeks of therapy was associated with human immunodeficiency virus type 1 (HIV-1) disease progression or death. Among 406 patients with AIDS and a first episode of Pneumocystis carinii pneumonia, 65% had measurable pretreatment concentrations of serum p24 antigen (≥10 ng/mL). Changes during treatment were not associated with reduced mortality. In 637 mildly symptomatic patients, 24% had measurable concentrations, and changes were marginally associated with increased time until more advanced disease. Among 683 asymptomatic patients, 18% had measurable concentrations, and changes were not associated with increased time until progression. Despite the small number of clinical events and the low rate of serum p24 antigen positivity in the latter two studies, pretreatment serum p24 antigen levels were predictive of clinical outcome; subsequent measurements appear to be of limited use in evaluating zidovudine therapy.

AB - Serum p24 antigen levels were examined in subjects from three clinical trials of zidovudine to determine whether the pattern of change in serum p24 antigen during the first 8-16 weeks of therapy was associated with human immunodeficiency virus type 1 (HIV-1) disease progression or death. Among 406 patients with AIDS and a first episode of Pneumocystis carinii pneumonia, 65% had measurable pretreatment concentrations of serum p24 antigen (≥10 ng/mL). Changes during treatment were not associated with reduced mortality. In 637 mildly symptomatic patients, 24% had measurable concentrations, and changes were marginally associated with increased time until more advanced disease. Among 683 asymptomatic patients, 18% had measurable concentrations, and changes were not associated with increased time until progression. Despite the small number of clinical events and the low rate of serum p24 antigen positivity in the latter two studies, pretreatment serum p24 antigen levels were predictive of clinical outcome; subsequent measurements appear to be of limited use in evaluating zidovudine therapy.

UR - http://www.scopus.com/inward/record.url?scp=0028314392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028314392&partnerID=8YFLogxK

M3 - Article

C2 - 8133085

AN - SCOPUS:0028314392

VL - 169

SP - 713

EP - 721

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 4

ER -